The Broader Market
A major pharmaceutical company (diabetes and weight-loss drugs) that uses AI in drug discovery.
{'verdict': 'No signals sit in the elevated band. Ranks 40th of 68 on composite fragility (F\xa038.7), below Lam Research and Disney.', 'as_of': '2026-07-11', 'source': 'engine-restatement (T1)', 'snapshot': {'composite_f': 38.7, 'n_elevated': 0, 'convergence': 'watch', 'rank': 40, 'elevated': []}}
The Insilico Medicine deal is $2.75B total — $115M upfront plus milestones. That number is larger than Lilly's FY2025 R&D spend on an entire quarter ($3.34B in Q2 2025 alone). Where is this deal in the 10-K?
It isn't. The sheet documents: 'Deal signed March 29, 2026 (after the FY2025 10-K period). NOT reflected in the FY2025 10-K. Verify via 8-K filed around March 2026.' The sheet also notes the $115M upfront is confirmed but the 8-K status is unconfirmed. The sheet explicitly flags this: 'Verify via 8-K filed around March 2026' is one of the ten architect verification items. A $2.75B milestone deal with a 'NOT reflected in 10-K' status means the FY2025 filing gives investors zero signal on this commitment.
R&D was $13.337B in FY2025 — that's 20.5% of $65.2B revenue. Lilly's historical R&D was ~25% of revenue. The GLP-1 windfall is masking an R&D funding decision: is the pipeline actually being built, or is the margin expansion coming from riding the tirzepatide wave while harvesting the pipeline budget?
The sheet raises this directly in Indicator 4: 'The catch: this margin is unusually high and is partly a reflection of under-investment in the post-GLP-1 pipeline. R&D as % of revenue is ~18-21% (lower than Lilly's historical ~25%). That means current margins benefit from the GLP-1 growth exceeding R&D spend; sustaining it requires continuous pipeline delivery.' At $13.337B R&D on $65.2B revenue, the percentage is trending down relative to revenue growth. The sheet flags this as the mechanism behind the 40.4% operating margin.
The Lilly Endowment sold $416M of LLY in six months. You say that's a charitable foundation diversifying a historical position, not a management signal. But a $416M institutional disposition over six months from the largest historical shareholder is still a supply overhang. When does that become relevant?
The sheet draws the line explicitly: 'This is NOT a management selling signal. It is a charitable foundation systematically diversifying a historical stock position.' The Endowment is a >10% beneficial owner and its Form 4 filings are institutional disposition of a concentrated philanthropic holding. The sheet excludes it from the management score. The relevant insider picture is: CEO Ricks bought ~$1.05M in August 2025, one EVP sold $2.88M via a pre-planned 10b5-1, and no other officer sold anything. The Endowment overhang is a supply question for the market, not a fragility signal from management conviction.